C4 Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from C4 Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 16% in 3 years; of every extra $100 of sales, $478 became extra profit. Higher than 93% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-108.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 83% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$478Sales grew 16% in 3 years; of every extra $100 of sales, $478 became extra profit.
Higher than 93% of Healthcare companies in United States.
Asset Productivity Ratio
+16% / -17%In 3 years sales changed by +16% while total assets changed by -17%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-15.5×Operating cash was negative last year, while some debt falls due within a year.
Higher than 50% of Healthcare companies in United States.
Cash Cushion Ratio
+48%Cash, after subtracting all debt, equals 48% of its market value (net cash).
Higher than 77% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
C4 Therapeutics, Inc. made a loss over the last year. C4 Therapeutics, Inc. owes $0.31 for every $1 it owns. C4 Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossC4 Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.52The share price is 1.52 times C4 Therapeutics, Inc.'s book value per share, lower than 66% of Healthcare companies in United States.
Market cap
$376 MThe total market value of all of C4 Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 51% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$247 MWhat C4 Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.01Net worth divided by the number of shares. The share price of $3.06 is 1.5 times this, which is the P/B above.
Return on equity (ROE)
-48.1%C4 Therapeutics, Inc. lost 48.1% of its shareholders' money over the last year, higher than 50% of Healthcare companies in United States.
Owes vs Owns
0.31×C4 Therapeutics, Inc. owes $0.31 for every $1 it owns (low), lower than 59% of Healthcare companies in United States.
Dividend yield
NoneC4 Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+1%Revenue rose 1% in the year to Dec 2025, and grew 5% a year on average over 3 years.
Profit growth
LossC4 Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-292.1%C4 Therapeutics, Inc. lost $292 for every $100 of revenue.
Cash vs debt
Net cashC4 Therapeutics, Inc. held $189 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For C4 Therapeutics, Inc.: $376 M ÷ $247 M (30 Jun 2026) = 1.5.
What is C4 Therapeutics, Inc.'s return on equity?
C4 Therapeutics, Inc. lost 48.1% of its shareholders' money over the last year, higher than 50% of Healthcare companies in United States.
How much does C4 Therapeutics, Inc. owe compared with what it owns?
C4 Therapeutics, Inc. owes $0.31 for every $1 it owns (low), lower than 59% of Healthcare companies in United States.
Does C4 Therapeutics, Inc. pay a dividend?
No. C4 Therapeutics, Inc. does not currently pay a dividend.
Is C4 Therapeutics, Inc.'s revenue growing?
Revenue rose 1% in the year to Dec 2025, and grew 5% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.